AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 20550973 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombus aspiration
Number of subjects: 0
Study 20551376 — intervention group
Group type: EXPERIMENTAL
Intervention: BACOPP regimen (bleomycin, adriamycin, cyclophosphamide, vincristine, procarbazine, and prednisone) administered in 6 to 8 cycles; 75% of treatment courses were administered according to protocol
Number of subjects: 65
Study 20551454 — intervention group
Group type: EXPERIMENTAL
Intervention: Reflux Disease Questionnaire (RDQ)
Number of subjects: 308
Study 20551454 — intervention group
Group type: EXPERIMENTAL
Intervention: Family practitioners
Number of subjects: 308
Study 20551454 — intervention group
Group type: EXPERIMENTAL
Intervention: Gastroenterologists
Number of subjects: 308
Study 20551454 — intervention group
Group type: COMPARATOR
Intervention: Esomeprazole (40 mg for 2 weeks)
Number of subjects: 308
Study 20553600 — intervention group
Group type: EXPERIMENTAL
Intervention: Adalimumab 40 mg every other week
Number of subjects: 326
Study 20554713 — intervention group
Group type: EXPERIMENTAL
Intervention: tesamorelin 2 mg sc daily
Number of subjects: 806
Study 20554713 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 806
Study 20555351 — intervention group
Group type: EXPERIMENTAL
Intervention: Narrow-band UVB radiation therapy (NB-UVB) for 6 weeks
Number of subjects: 14
Study 20555351 — intervention group
Group type: EXPERIMENTAL
Intervention: Narrow-band UVB radiation therapy (NB-UVB)
Number of subjects: 14
Study 20557308 — intervention group
Group type: EXPERIMENTAL
Intervention: GeneSearch Breast Lymph Node (BLN) Assay
Number of subjects: 97
Study 20558556 — intervention group
Group type: EXPERIMENTAL
Intervention: REVEAL patients
Number of subjects: 2967
Study 20559034 — intervention group
Group type: EXPERIMENTAL
Intervention: Single vaccination with a split virion, inactivated, adjuvanted pandemic H1N1 influenza vaccine (A/California/7/2009)
Number of subjects: 160
Study 20560801 — intervention group
Group type: EXPERIMENTAL
Intervention: Storage time at -20°C
Number of subjects: 534
Study 20560883 — intervention group
Group type: EXPERIMENTAL
Intervention: Rectal luminal lactate concentration
Number of subjects: 130
Study 20560883 — intervention group
Group type: EXPERIMENTAL
Intervention: Arterial blood lactate concentration
Number of subjects: 130
Study 20560883 — intervention group
Group type: EXPERIMENTAL
Intervention: Rectal-arterial difference of lactate concentration
Number of subjects: 130
Study 20560883 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood pressure, noradrenaline dose, central venous oxygen saturation
Number of subjects: 130
Study 20561184 — intervention group
Group type: EXPERIMENTAL
Intervention: Isolated DVT
Number of subjects: 646
Study 20561184 — intervention group
Group type: COMPARATOR
Intervention: Isolated PE
Number of subjects: 646
Study 20561184 — intervention group
Group type: EXPERIMENTAL
Intervention: DVT and PE
Number of subjects: 646
Study 20561184 — intervention group
Group type: COMPARATOR
Intervention: Isolated DVT vs. Isolated PE
Number of subjects: 646
Study 20562120 — intervention group
Group type: EXPERIMENTAL
Intervention: Obstructive sleep apnoea (OSA) patients with left ventricular diastolic dysfunction
Number of subjects: 150
Study 20562120 — intervention group
Group type: EXPERIMENTAL
Intervention: Mean nocturnal oxygen saturation
Number of subjects: 150
Study 20562120 — intervention group
Group type: EXPERIMENTAL
Intervention: Age ≥ 58 yrs
Number of subjects: 150
Study 20562120 — intervention group
Group type: EXPERIMENTAL
Intervention: Mean nocturnal oxygen saturation < 92%
Number of subjects: 150
Study 20562120 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinic systolic blood pressure and mean nocturnal oxygen saturation
Number of subjects: 150
Study 20562120 — intervention group
Group type: EXPERIMENTAL
Intervention: Left ventricular hypertrophy
Number of subjects: 150
Study 20562130 — intervention group
Group type: EXPERIMENTAL
Intervention: Lung injury prediction score (derived from logistic regression analysis)
Number of subjects: 872
Study 20562130 — intervention group
Group type: EXPERIMENTAL
Intervention: Lung injury prediction score (validated in an independent cohort)
Number of subjects: 872
Study 20562526 — intervention group
Group type: EXPERIMENTAL
Intervention: Co-culture of immortalized human fibroblasts with MCF7 breast cancer cells
Number of subjects: 0
Study 20562526 — intervention group
Group type: EXPERIMENTAL
Intervention: siRNA-mediated Cav-1 downregulation
Number of subjects: 0
Study 20562526 — intervention group
Group type: EXPERIMENTAL
Intervention: Chloroquine or other autophagy/lysosome inhibitors
Number of subjects: 0
Study 20564111 — intervention group
Group type: EXPERIMENTAL
Intervention: Tumor diameter >5 cm
Number of subjects: 644
Study 20564111 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinically positive nodes (N+)
Number of subjects: 644
Study 20564111 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of tumor diameter >5 cm and N+
Number of subjects: 644
Study 20564111 — intervention group
Group type: EXPERIMENTAL
Intervention: Male sex
Number of subjects: 644
Study 20564750 — intervention group
Group type: EXPERIMENTAL
Intervention: Multilevel surgical treatment (uvulopalatopharyngoplasty, tonsillectomy, genioglossus advancement, with or without hyoid suspension)
Number of subjects: 30
Study 20564750 — intervention group
Group type: EXPERIMENTAL
Intervention: Multilevel surgical treatment
Number of subjects: 30
Study 20565828 — intervention group
Group type: EXPERIMENTAL
Intervention: Colon Capsule Endoscopy (CCE)
Number of subjects: 59
Study 20565828 — intervention group
Group type: COMPARATOR
Intervention: Conventional Colonoscopy (CSPY)
Number of subjects: 59
Study 20566896 — intervention group
Group type: EXPERIMENTAL
Intervention: Deferasirox
Number of subjects: 116
Study 20566896 — intervention group
Group type: EXPERIMENTAL
Intervention: Deferasirox (chelation-naive)
Number of subjects: 116
Study 20566896 — intervention group
Group type: EXPERIMENTAL
Intervention: Deferasirox (previously chelated)
Number of subjects: 116
Study 20569704 — intervention group
Group type: EXPERIMENTAL
Intervention: Frequent optimization of AV and VV delays every 3 months using a new device-based algorithm.
Number of subjects: 1580
Study 20569704 — intervention group
Group type: COMPARATOR
Intervention: Standard of care arm (empiric device programming or non-device-based method of CRT optimization).
Number of subjects: 1580
Study 20569720 — intervention group
Group type: EXPERIMENTAL
Intervention: Carotid ultrasound with measurement of intima-media thickness (IMT)
Number of subjects: 150
Study 20570701 — intervention group
Group type: COMPARATOR
Intervention: Multi-item lunch (AN)
Number of subjects: 0
Study 20570701 — intervention group
Group type: COMPARATOR
Intervention: Macaroni and cheese lunch (AN)
Number of subjects: 0
Study 20570701 — intervention group
Group type: COMPARATOR
Intervention: Yogurt snack (AN)
Number of subjects: 0
Study 20571134 — intervention group
Group type: COMPARATOR
Intervention: Control arm (no screening)
Number of subjects: 38350
Study 20571134 — intervention group
Group type: EXPERIMENTAL
Intervention: Screened arm (with PSA and DRE screening)
Number of subjects: 38350
Study 20573151 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture (twice on the same day at acupuncture point GV20 and bilaterally at points BL67, LI4 and SP6)
Number of subjects: 125
Study 20573151 — intervention group
Group type: COMPARATOR
Intervention: Sham acupuncture (at the same points)
Number of subjects: 125
Study 20573639 — intervention group
Group type: EXPERIMENTAL
Intervention: Be Fit, Be Well
Number of subjects: 1100
Study 20573639 — intervention group
Group type: EXPERIMENTAL
Intervention: POWER Hopkins
Number of subjects: 1100
Study 20573639 — intervention group
Group type: EXPERIMENTAL
Intervention: POWER-UP
Number of subjects: 1100
Study 20573788 — intervention group
Group type: EXPERIMENTAL
Intervention: VAT (visceral adipose tissue) categorized into tertiles
Number of subjects: 99
Study 20573788 — intervention group
Group type: COMPARATOR
Intervention: African American group
Number of subjects: 99
Study 20573788 — intervention group
Group type: EXPERIMENTAL
Intervention: VAT
Number of subjects: 99
Study 20573788 — intervention group
Group type: EXPERIMENTAL
Intervention: HFF
Number of subjects: 99
Study 20573794 — intervention group
Group type: EXPERIMENTAL
Intervention: Citrus consumption (proline betaine as a biomarker)
Number of subjects: 1998
Study 20573794 — intervention group
Group type: EXPERIMENTAL
Intervention: Citrus consumers
Number of subjects: 1998
Study 20573794 — intervention group
Group type: COMPARATOR
Intervention: Noncitrus consumers
Number of subjects: 1998
Study 20576011 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin (IVIG) administration
Number of subjects: 24
Study 20576011 — intervention group
Group type: EXPERIMENTAL
Intervention: IVIG administration
Number of subjects: 24
Study 20576011 — intervention group
Group type: EXPERIMENTAL
Intervention: Serial testing before and after IVIG
Number of subjects: 24
Study 20576011 — intervention group
Group type: EXPERIMENTAL
Intervention: IVIG products
Number of subjects: 24
Study 20576398 — intervention group
Group type: EXPERIMENTAL
Intervention: Carotid artery stenting (CAS)
Number of subjects: 5297
Study 20579539 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary flow reserve (CFR) after intracoronary adenosine
Number of subjects: 189
Study 20579539 — intervention group
Group type: EXPERIMENTAL
Intervention: CFR <2.32
Number of subjects: 189
Study 20579539 — intervention group
Group type: EXPERIMENTAL
Intervention: CFR <2.32 among women without obstructive CAD
Number of subjects: 189
Study 20579539 — intervention group
Group type: EXPERIMENTAL
Intervention: CFR
Number of subjects: 189
Study 20579630 — intervention group
Group type: EXPERIMENTAL
Intervention: 20% topical autologous serum
Number of subjects: 165
Study 20579630 — intervention group
Group type: COMPARATOR
Intervention: No use of topical autologous serum
Number of subjects: 165
Study 20581689 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibrinogen levels in the highest tertile (>406 mg/dL)
Number of subjects: 922
Study 20581689 — intervention group
Group type: EXPERIMENTAL
Intervention: High CRP (>3 mg/L)
Number of subjects: 922
Study 20581689 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibrinogen (as a linear variable) per 100 mg/dL increase
Number of subjects: 922
Study 20582937 — intervention group
Group type: EXPERIMENTAL
Intervention: Bortezomib 1.3 mg/m(2) with VXLD chemotherapy
Number of subjects: 10
Study 20582937 — intervention group
Group type: EXPERIMENTAL
Intervention: Bortezomib 1 mg/m(2) with VXLD chemotherapy
Number of subjects: 10
Study 20582937 — intervention group
Group type: EXPERIMENTAL
Intervention: Bortezomib with VXLD chemotherapy
Number of subjects: 10
Study 20584275 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavior therapy (N = 12)
Number of subjects: 24
Study 20584275 — intervention group
Group type: COMPARATOR
Intervention: Minimal attention control (N = 12)
Number of subjects: 24
Study 20584291 — intervention group
Group type: EXPERIMENTAL
Intervention: HES 200/0.5 (10%)
Number of subjects: 30
Study 20584291 — intervention group
Group type: COMPARATOR
Intervention: Crystalloids only
Number of subjects: 30
Study 20584327 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain Cluster
Number of subjects: 788
Study 20584327 — intervention group
Group type: EXPERIMENTAL
Intervention: Fatigue Cluster
Number of subjects: 788
Study 20584327 — intervention group
Group type: EXPERIMENTAL
Intervention: Domestic Cluster
Number of subjects: 788
Study 20584327 — intervention group
Group type: EXPERIMENTAL
Intervention: Impairment Cluster
Number of subjects: 788
Study 20584327 — intervention group
Group type: EXPERIMENTAL
Intervention: Affective Cluster
Number of subjects: 788
Study 20584327 — intervention group
Group type: EXPERIMENTAL
Intervention: Social Cluster
Number of subjects: 788
Study 20584542 — intervention group
Group type: EXPERIMENTAL
Intervention: Pazopanib 800 mg once daily until PD or unacceptable toxicity
Number of subjects: 36
Study 20584542 — intervention group
Group type: EXPERIMENTAL
Intervention: Pazopanib 800 mg once daily
Number of subjects: 36
Study 20585012 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulmonary vascular resistance >32 Wood units
Number of subjects: 2716
Study 20585012 — intervention group
Group type: EXPERIMENTAL
Intervention: PAH associated with portal hypertension
Number of subjects: 2716
Study 20585012 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified New York Heart Association/World Health Organization functional class IV
Number of subjects: 2716
Study 20585012 — intervention group
Group type: EXPERIMENTAL
Intervention: Men >60 years of age
Number of subjects: 2716
Study 20585012 — intervention group
Group type: EXPERIMENTAL
Intervention: Family history of PAH
Number of subjects: 2716
Study 20585012 — intervention group
Group type: EXPERIMENTAL
Intervention: Renal insufficiency
Number of subjects: 2716
Study 20585012 — intervention group
Group type: EXPERIMENTAL
Intervention: PAH associated with connective tissue disease
Number of subjects: 2716
Study 20585012 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional class III
Number of subjects: 2716
Study 20585012 — intervention group
Group type: EXPERIMENTAL
Intervention: Mean right atrial pressure
Number of subjects: 2716
Study 20585012 — intervention group
Group type: EXPERIMENTAL
Intervention: Resting systolic blood pressure and heart rate
Number of subjects: 2716
Study 20585012 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-minute walk distance
Number of subjects: 2716
Study 20585012 — intervention group
Group type: EXPERIMENTAL
Intervention: Brain natriuretic peptide
Number of subjects: 2716
Study 20585012 — intervention group
Group type: EXPERIMENTAL
Intervention: Percent predicted carbon monoxide diffusing capacity
Number of subjects: 2716
Study 20585012 — intervention group
Group type: EXPERIMENTAL
Intervention: Pericardial effusion on echocardiogram
Number of subjects: 2716
Study 20588167 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV-infected patients
Number of subjects: 78
Study 20589868 — intervention group
Group type: EXPERIMENTAL
Intervention: Subthalamic nucleus deep brain stimulation (STN-DBS)
Number of subjects: 123
Study 20589868 — intervention group
Group type: COMPARATOR
Intervention: Best medical treatment (BMT)
Number of subjects: 123
Study 20591142 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary prevention of cardiovascular disease (CVD)
Number of subjects: 7641
Study 20591142 — intervention group
Group type: EXPERIMENTAL
Intervention: Physician-level assessment
Number of subjects: 7641
Study 20591142 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-level assessment
Number of subjects: 7641
Study 20591142 — intervention group
Group type: EXPERIMENTAL
Intervention: Fasting blood sample analysis
Number of subjects: 7641
Study 20591191 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotics (Lactobacillus rhamnosus GR-1 and Lactobacillus reuteri RC-14), 2 capsules a day for 6-12 weeks, up to the 24th-25th week of gestation.
Number of subjects: 0
Study 20591191 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 20593018 — intervention group
Group type: EXPERIMENTAL
Intervention: rdESAT-6 and CFP-10 skin test reagent (0.01 microg or 0.1 microg injected intradermally)
Number of subjects: 42
Study 20594195 — intervention group
Group type: EXPERIMENTAL
Intervention: Bendamustine 90 mg/m²
Number of subjects: 9
Study 20594195 — intervention group
Group type: EXPERIMENTAL
Intervention: Bendamustine 120 mg/m²
Number of subjects: 9
Study 20595284 — intervention group
Group type: EXPERIMENTAL
Intervention: Adalimumab 40 mg subcutaneous injections every other week
Number of subjects: 127
Study 20595516 — intervention group
Group type: EXPERIMENTAL
Intervention: Allogeneic stem cell transplantation (alloSCT) with fludarabine/cyclophosphamide-based conditioning
Number of subjects: 100
Study 20595516 — intervention group
Group type: EXPERIMENTAL
Intervention: Allogeneic stem cell transplantation (alloSCT) with MRD monitoring
Number of subjects: 100
Study 20595516 — intervention group
Group type: EXPERIMENTAL
Intervention: Allogeneic stem cell transplantation (alloSCT)
Number of subjects: 100
Study 20597081 — intervention group
Group type: EXPERIMENTAL
Intervention: Pa-Never
Number of subjects: 1700
Study 20597081 — intervention group
Group type: EXPERIMENTAL
Intervention: Pa-Past
Number of subjects: 1700
Study 20597081 — intervention group
Group type: EXPERIMENTAL
Intervention: Diagnosis after newborn or prenatal screening
Number of subjects: 1700
Study 20597081 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal smoking during pregnancy
Number of subjects: 1700
Study 20598482 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic neovascularization
Number of subjects: 47
Study 20598570 — intervention group
Group type: EXPERIMENTAL
Intervention: Retrievable Option inferior vena cava (IVC) filter
Number of subjects: 100
Study 20598843 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-HTTLPR genotype
Number of subjects: 176
Study 20598843 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-HTTLPR polymorphism
Number of subjects: 176
Study 20599053 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Fear-Avoidance Beliefs Questionnaire (FABQ)
Number of subjects: 80
Study 20599053 — intervention group
Group type: EXPERIMENTAL
Intervention: Tampa Scale of Kinesiophobia (TSK-11)
Number of subjects: 80
Study 20599053 — intervention group
Group type: EXPERIMENTAL
Intervention: Shoulder Pain and Disability Index (SPADI)
Number of subjects: 80
Study 20599053 — intervention group
Group type: EXPERIMENTAL
Intervention: FABQ-W (work beliefs subscale)
Number of subjects: 80
Study 20599188 — intervention group
Group type: EXPERIMENTAL
Intervention: GSK598809 (selective D(3) receptor antagonist)
Number of subjects: 19
Study 20599337 — intervention group
Group type: EXPERIMENTAL
Intervention: Couples-based intervention for self-management of hyperlipidemia
Number of subjects: 250
Study 20602477 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirolimus-eluting stents (SES)
Number of subjects: 187
Study 20602477 — intervention group
Group type: EXPERIMENTAL
Intervention: Zotarolimus-eluting stents (ZES)
Number of subjects: 187
Study 20602477 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus-eluting stents (EvES)
Number of subjects: 187
Study 20602477 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall (all groups)
Number of subjects: 187
Study 20605360 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 17
Study 20605397 — intervention group
Group type: EXPERIMENTAL
Intervention: Microwave ablation (MWA)
Number of subjects: 29
Study 20605934 — intervention group
Group type: EXPERIMENTAL
Intervention: SU14813 (200 mg/day on schedule 4/1)
Number of subjects: 77
Study 20605934 — intervention group
Group type: EXPERIMENTAL
Intervention: SU14813 (100 mg/day with continuous daily dosing)
Number of subjects: 77
Study 20605934 — intervention group
Group type: EXPERIMENTAL
Intervention: SU14813
Number of subjects: 77
Study 20606544 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab administered intravenously at 375 mg/m2 on each of 4 consecutive weeks with conventional immunotherapy (Group I and II)
Number of subjects: 25
Study 20606544 — intervention group
Group type: COMPARATOR
Intervention: Rituximab administered intravenously at 375 mg/m2 on each of 4 consecutive weeks without conventional immunotherapy (Group III)
Number of subjects: 25
Study 20606544 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab dosing based on body weight
Number of subjects: 25
Study 20606683 — intervention group
Group type: EXPERIMENTAL
Intervention: Aromatase inhibitor therapy (AI); specific dosage and duration not mentioned.
Number of subjects: 52
Study 20606683 — intervention group
Group type: COMPARATOR
Intervention: Control group (without AIMSS); specific dosage and duration not mentioned.
Number of subjects: 52
Study 20608766 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline IP-10 < 150 pg/ml
Number of subjects: 21
Study 20608766 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline IP-10 levels
Number of subjects: 21
Study 20609468 — intervention group
Group type: EXPERIMENTAL
Intervention: Olaparib 400 mg twice daily
Number of subjects: 57
Study 20609468 — intervention group
Group type: EXPERIMENTAL
Intervention: Olaparib 100 mg twice daily
Number of subjects: 57
Study 20609706 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirna-027 (100, 200, 400, 800, 1200, or 1600 microg/eye)
Number of subjects: 26
Study 20609706 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirna-027 (100 and 200 microg doses)
Number of subjects: 26
Study 20609706 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirna-027 (up to 1600 microg/eye)
Number of subjects: 26
Study 20610186 — intervention group
Group type: EXPERIMENTAL
Intervention: Donepezil 10 mg daily for 90 days
Number of subjects: 30
Study 20610635 — intervention group
Group type: EXPERIMENTAL
Intervention: Elevated bone turnover (EBT) group (n = 13)
Number of subjects: 39
Study 20610635 — intervention group
Group type: COMPARATOR
Intervention: Normal bone turnover group
Number of subjects: 39
Study 20610635 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional support (not quantified in the abstract)
Number of subjects: 39
Study 20615492 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined surgery (n = 64)
Number of subjects: 120
Study 20615492 — intervention group
Group type: COMPARATOR
Intervention: Consecutive surgery (n = 56)
Number of subjects: 120
Study 20616117 — intervention group
Group type: EXPERIMENTAL
Intervention: Sarcopenia
Number of subjects: 275
Study 20616163 — intervention group
Group type: EXPERIMENTAL
Intervention: Holter monitoring in patients on hemodialysis
Number of subjects: 239
Study 20617532 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of anti-Sa antibodies at inclusion, especially at higher titers
Number of subjects: 253
Study 20617532 — intervention group
Group type: EXPERIMENTAL
Intervention: Low titer of any particular antibody
Number of subjects: 253
Study 20617532 — intervention group
Group type: EXPERIMENTAL
Intervention: Reversion of RF and anti–CCP-2 antibodies
Number of subjects: 253
Study 20617532 — intervention group
Group type: EXPERIMENTAL
Intervention: Acquisition of RF or anti–CCP-2 after inclusion
Number of subjects: 253
Study 20617532 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial positivity for RF and anti–CCP-2 antibodies
Number of subjects: 253
Study 20617532 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-CCP-2 prevalence
Number of subjects: 253
Study 20617532 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of anti-Sa antibodies
Number of subjects: 253
Study 20619378 — intervention group
Group type: EXPERIMENTAL
Intervention: Invaplex 50 (100%)
Number of subjects: 32
Study 20619378 — intervention group
Group type: EXPERIMENTAL
Intervention: S. flexneri 2a LPS (71%)
Number of subjects: 32
Study 20619378 — intervention group
Group type: EXPERIMENTAL
Intervention: 240 microg dose
Number of subjects: 32